循環器ジャーナル67巻1号

2019年01月発行

特集 循環器の現場からの検証：そのエビデンスを日本で活用するには？ Ⅱ．予防医療

わが国で血圧はどこまで下げるか—SPRINT試験の現実的な解釈を巡って

著者： 浅山敬¹² 大久保孝義¹²

所属機関： ¹帝京大学医学部衛生学公衆衛生学 ²東北血圧管理協会

ページ範囲：P.34 - P.41

Point
・SPRINTではAOBPという厳格な外来血圧測定方法が用いられ，わが国の実地臨床で用いる血圧とは異なる．
・SPRINTの登録基準に適合し，そのまま結果が当てはめられるのは米国の治療中患者でも6人に1人である．
・最近の欧米ガイドラインの収縮期降圧目標130mmHgがわが国でも臨床的に適用可能かは慎重な解釈が求められる．

参考文献

1) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial（ALLHAT）. JAMA 288:2981-2997, 2002

2) Whelton PK, Carey RM, Aronow WS, et al:2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:e13-e115, 2018

3) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:a meta-analysis. Lancet 358:1305-1315, 2001

4) SPRINT Research Group, Wright JT Jr., Williamson JD, et al:A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373:2103-2116, 2015

5) Ambrosius WT, Sink KM, Foy CG, et al:The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure:the Systolic Blood Pressure Intervention Trial（SPRINT）. Clin Trials 11:532-546, 2014

6) Williamson JD, Supiano MA, Applegate WB, et al:Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged＞/＝75 Years:A Randomized Clinical Trial. JAMA 315:2673-2682, 2016

7) Wright JT Jr., Whelton PK, Reboussin DM:A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 374:2294, 2016

8) Beddhu S, Chertow GM, Cheung AK, et al:Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation 137:134-143, 2018

9) Berlowitz DR, Foy CG, Kazis LE, et al:Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med 377:733-744, 2017

10) Zoungas S, Chalmers J, Neal B, et al:Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371:1392-1406, 2014

11) Burns NS, Miller PW:Learning What We Didn't Know-The SPRINT Data Analysis Challenge. N Engl J Med 376:2205-2207, 2017

12) Markovitz AA, Mack JA, Nallamothu BK, et al:Incremental effects of antihypertensive drugs:instrumental variable analysis. BMJ 359:j5542, 2017

13) Cushman WC, Evans GW, Byington RP, et al:Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575-1585, 2010

14) Kalkman DN, Brouwer TF, Vehmeijer JT, et al:J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets:An Experimental Approach to an Observational Paradigm. Circulation 136:2220-2229, 2017

15) Drawz PE, Pajewski NM, Bates JT, et al:Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure:Results From the SPRINT（Systolic Blood Pressure Intervention Trial）Ambulatory Blood Pressure Study. Hypertension 69:42-50, 2017

16) Myers MG:A Short History of Automated Office Blood Pressure-15 Years to SPRINT. J Clin Hypertens（Greenwich）18:721-724, 2016

17) Pandit JA, Batlle D:Snapshot Hemodynamics and Clinical Outcomes in Hypertension:Precision in the Measurements Is Key. Hypertension 67:270-271, 2016

18) Johnson KC, Whelton PK, Cushman WC, et al:Blood Pressure Measurement in SPRINT（Systolic Blood Pressure Intervention Trial）. Hypertension 71:848-857, 2018

19) Leung AA, Daskalopoulou SS, Dasgupta K, et al:Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol 33:557-576, 2017

20) Stergiou GS, Doumas M, Kollias A, et al:Important practice lessons from the SPRINT study beyond the blood pressure goal:all well known and now confirmed. J Am Soc Hypertens 10:613-617, 2016

21) Filipovsky J, Seidlerova J, Kratochvil Z, et al:Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press 25:228-234, 2016

22) Bauer F, Seibert FS, Rohn B, et al:Attended Versus Unattended Blood Pressure Measurement in a Real Life Setting. Hypertension 71:243-249, 2018

23) World Health Organization. World Health Organization Collaborating Centre for Drug Statistics Methodology System of Defined Daily Doses. 2011（Accessed August 23, 2011, at http://www.whocc.no/atc_ddd_index/.）

24) Roush GC, Ernst ME, Kostis JB, et al:Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone:antihypertensive and metabolic effects. Hypertension 65:1041-1046, 2015

25) Bress AP, Tanner RM, Hess R, et al:Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol 67:463-472, 2016

26) Williams B, Mancia G, Spiering W, et al;ESC Scientific Document Group:2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021-3104, 2018

27) Shimamoto K, Ando K, Fujita T, et al:The Japanese Society of Hypertension Guidelines for the Management of Hypertension（JSH 2014）. Hypertens Res 37:253-390, 2014